• US approves AbbVie/Neurocrine’s uterine pain drug pharmatimes
    July 26, 2018
    AbbVie and Neurocrine have announced the US approval of Orilissa, the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.
PharmaSources Customer Service